Skip to main content

Advertisement

SpringerLink
Log in

Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objectives

This study aims to compare the efficacy and the safety of the iguratimod with placebo and other disease-modifying antirheumatic drugs (DMARDs) in adults with rheumatoid arthritis.

Methods

Two authors independently searched and selected randomized controlled trials from Cochrane library, Medline (through Pubmed), and Chinese databases, and then assessed the risk of bias (using ROB 2 tool), and graded the certainty of evidence (using the GRADEpro GDT software). We applied the RevMan 5 software for performing meta-analyses of the final consensus data.

Results

We identified 12 trials involving 1938 participants. Ten trials had an overall high risk of bias. Although iguratimod had superior efficacy than placebo, the incidence of adverse events was also higher. Inferring to non-inferiority analysis with other DMARD therapy (primarily comprising methotrexate), iguratimod is likely to result in similar treatment response (20% (OR 1.04, 95% CI 0.79 to 1.36), 50% and 70% improvement in American College of Rheumatology criteria) and functional ability at 24 weeks. Although the disease state was slightly better with iguratimod (MD − 0.55, 95% CI − 0.85 to − 0.25), a clinically important improvement was not achieved. Iguratimod may have lower C-reactive protein and erythrocyte sedimentation rate values. Swollen joint count, tender joint count, pain intensity, and patient’s and physician’s global assessment of disease state may be comparable between the therapies. Both the therapies are likely to have similar odds (OR 0.91, 95% CI 0.67 to 1.26) of adverse events.

Conclusion

Our evidence suggests that iguratimod may be considered a potential alternative to methotrexate to treat rheumatoid arthritis.

Key Points

• The Asia Pacific League of Association for Rheumatology (APLAR) has recommended that iguratimod may be used a first-line drug for rheumatoid arthritis in specific cases.

• Patients on iguratimod may have similar treatment response, functional ability, disease state, and adverse event profile at 24 weeks compared with those on methotrexate.

• Iguratimod may be considered a better alternative to methotrexate in RA patients having high CRP and ESR values.

• Future clinical trials in diverse population comparing the efficacy and safety of iguratimod in monotherapy or combination therapy with DMARDs (other than methotrexate) are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Alteha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham Iii CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62(9):2569–2581

    Article  Google Scholar 

  2. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, Mcinnes IB, Solomon DH, Strand V, Yamamoto K (2018) Rheumatoid arthritis. Nat Rev Dis Primers 4:18001. https://doi.org/10.1038/nrdp.2018.1

    Article  PubMed  Google Scholar 

  3. Smolen JS, Aletaha D, Mcinnes IB (2016) Rheumatoid arthritis. Lancet 388(10055):2023–2038. https://doi.org/10.1016/S0140-6736(16)30173-8

    Article  CAS  PubMed  Google Scholar 

  4. Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao FF, Gu Y, Wu XX, Shen Y, Xu Q (2013) A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol 191(10):4969–4978

    Article  CAS  PubMed  Google Scholar 

  5. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, Van Vollenhoven R (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76(6):960–977

    Article  PubMed  Google Scholar 

  6. Alteha D, Smolen JS (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA 320(13):1360–1372

    Article  Google Scholar 

  7. Weinblatt ME (2013) Methotrexate in rheumatoid arthritis: a quarter century of development. Trans Am Clin Climatol Assoc 124:16

    PubMed  PubMed Central  Google Scholar 

  8. Halilova KI, Brown EE, Morgan SL, Bridges SL, Hwang M-H, Arnett DK, Danila MI (2012) Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand? Int J Rheumatol 2012. https://doi.org/10.1155/2012/978396

  9. Lau CS, Chia F, Dans L, Harrison A, Hsieh TY, Jain R, Jung SM, Kishimoto M, Kumar A, Leong KP (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22(3):357-75. https://doi.org/10.1111/1756-185X.13513

  10. Tanaka K, Yamaguchi T, Hara M (2015) Iguratimod for the treatment of rheumatoid arthritis in Japan. Expert Rev Clin Immunol 11(5):565–573

    Article  CAS  PubMed  Google Scholar 

  11. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, Aoyagi T, Furuichi I, Nakashima T, Migita K (1999) Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 133(6):566–574

    Article  CAS  PubMed  Google Scholar 

  12. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, Inoue K, Kusaka Y, Kondo M, Sano H (2001) Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 28(12):2591–2596

    CAS  PubMed  Google Scholar 

  13. Wei Y, Sun XX, Hua MH, Tan WF, Wang F, Zhang MJ (2015) Inhibitory effect of a novel antirheumatic drug T-614 on the IL-6-induced RANKL/OPG, IL-17, and MMP-3 expression in synovial fibroblasts from rheumatoid arthritis patients. Biomed Res Int 2015. https://doi.org/10.1155/2015/214683

  14. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C (1992) Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. Aust J Pharm 15(11):649–655

    CAS  Google Scholar 

  15. Tokai N, Yoshida S, Kotani T, Yoshikawa A, Kimura Y, Fujiki Y, Matsumura Y, Takeuchi T, Makino S, Arawaka S (2018) Serum matrix metalloproteinase 3 levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs in patients with rheumatoid arthritis. PLoS One 13(8):e0202601

    Article  PubMed  PubMed Central  Google Scholar 

  16. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, Muraguchi A (2003) Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology 42(11):1365–1371

    Article  CAS  PubMed  Google Scholar 

  17. Song JL, Liu HL, Zhu Q, Miao YT, Wang FY, Yang F, Cheng WJ, Xi YB, Niu XY, He DY (2018) T-614 Promotes osteoblastic cell differentiation by increasing Dlx5 expression and regulating the activation of p38 and NF-κB. Biomed Res Int 2018. https://doi.org/10.1155/2018/4901591

  18. Wang X, Li P, Xu T, Ding R, Zhang X, Bi L (2016) Effect of iguratimod and methotrexate on RANKL and OPG expression in serum and IL-1β-induced fibroblast-like synoviocytes from patients with rheumatoid arthritis. Cell Mol Biol 62(12):44–50

    Article  CAS  PubMed  Google Scholar 

  19. Gan K, Yang LL, Xu LX, Feng XK, Zhang QD, Wang F, Tan WF, Zhang MJ (2016) Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264. 7 cells via NF-κB and MAPK pathways. Int Immunopharmacol 35:294–300

    Article  CAS  PubMed  Google Scholar 

  20. Li JT, Mao HJ, Liang Y, Lu YR, Chen S, Yang NP, Shi GX (2013) Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin Dev Immunol 2013. https://doi.org/10.1155/2013/310628

  21. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, Katz LM, Lightfoot R Jr, Paulus H, Strand V (1995) American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727–735

    Article  CAS  PubMed  Google Scholar 

  22. Bruce B, Fries J (2005) The health assessment questionnaire (HAQ). Clin Exp Rheumatol 23(5):S14

    CAS  PubMed  Google Scholar 

  23. Smolen J, Aletaha D (2010) The assessment of disease activity in rheumatoid arthritis. Clin Exp Rheumatol 28(3):S18

    PubMed  Google Scholar 

  24. Nikiphorou E, Radner H, Chatzidionysiou K, Desthieux C, Zabalan C, Van Eijk-Hustings Y, Dixon WG, Hyrich KL, Askling J, Gossec L (2016) Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. Arthritis Res Ther 18(1):251

    Article  PubMed  PubMed Central  Google Scholar 

  25. Harrington JT (2009) The uses of disease activity scoring and the physician global assessment of disease activity for managing rheumatoid arthritis in rheumatology practice. J Rheumatol 36(5):925–929

    Article  PubMed  Google Scholar 

  26. Review Manager 5 (RevMan 5) (2014). vol 5.3. Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen

  27. Group GW (2004) Grading quality of evidence and strength of recommendations. BMJ 328(7454):1490

    Article  Google Scholar 

  28. Schünemann H, Brożek J, Guyatt GH, Oxman AD, Editor(S) (2013) Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group,

  29. GRADEpro GDT: GRADEpro Guideline Development Tool (2015). McMaster University (developed by Evidence Prime), Hamilton (ON)

  30. Higgins JP, Sterne JA, Savovic J, Page MJ, Hróbjartsson A, Boutron I, Reeves B, Eldridge S (2016) A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev 10(Suppl 1):29–31

    Google Scholar 

  31. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, Devereaux P, Montori VM, Freyschuss B, Vist G (2011) GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 64(12):1283–1293

    Article  PubMed  Google Scholar 

  32. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M (2007) Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 17(1):1–9

    Article  PubMed  Google Scholar 

  33. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, Yang NP, Zhao YH, Chen ZW, Xu JH (2009) Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Care Res 61(7):979–987

    Article  CAS  Google Scholar 

  34. Lu LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, Li XF, Wu HX (2008) Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J 121(7):615–619

    Article  CAS  PubMed  Google Scholar 

  35. Zhao L, Jiang ZY, Zhang YD, Ma HS, Cai CL (2017) Analysis of efficacy and safety of treatment of active rheumatoid arthritis with iguratimod and methotrexate. Biomed Res Int 28(5):2353–2359

    CAS  Google Scholar 

  36. Liu Y, Shen H (2018) Clinical trial iguratimod tablets combined with tripterysium glycosides tablets in the treatment of elderly patients with active rheumatoid arthritis. Chin J Clin Pharmacol 34(19):2283–2286. https://doi.org/10.13699/j.cnki.1001-6821.2018.19.012

  37. Wang XT, Ma CL, Li P, Zhao F, Bi LQ (2017) Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin Rheumatol 36(6):1369–1377

    Article  PubMed  Google Scholar 

  38. Xu YZ, Zhu Q, Song J, Liu HL, Miao YT, Yang F, Wang FY, Cheng WJ, Xi YB, Niu XY (2015) Regulatory effect of iguratimod on the balance of Th subsets and inhibition of inflammatory cytokines in patients with rheumatoid arthritis. Mediat Inflamm 2015. https://doi.org/10.1155/2015/356040

  39. Zhao WM, Yao DY, Huo HS, Qin CM, Wei QJ (2016) Clinical study of iguratimod in the treatment of active rheumatoid arthritis. Chin J Postgraduates Med 39(05):450–452. https://doi.org/10.3760/cma.J.jssn.1673-4904.2016.05.017

    Article  Google Scholar 

  40. Xia Z, Lyu J, Hou N, Song L, Li X, Liu H (2016) Iguratimod in combination with methotrexate in active rheumatoid arthritis. Z Rheumatol 75(8):828–833. https://doi.org/10.1007/s00393-015-1641-y

  41. Hu HL (2014) Clinical effect and safety of iguratimod for treating rheumatoid arthritis. Suzhou University

  42. Xiong YM, Fan SN, Zou L (2015) Study on the effect of iguratimod combined with methotrexate on the anti-guanine peptide antibody and other indicators in patients with rheumatoid arthritis. J Clin Med 32(12):833–835

    CAS  Google Scholar 

  43. Xu BJ, Mo SQ, Xue XQ (2015) Clinical effect of methotrexate combined with iguratimod on treatment of rheumatoid arthritis. J Clin Med Pract 19(01):120–122. https://doi.org/10.7619/jcmp.201501038

    Article  CAS  Google Scholar 

  44. Ward MM, Guthrie LC, Alba MI (2015) Clinically important changes in individual and composite measures of rheumatoid arthritis activity: thresholds applicable in clinical trials. Ann Rheum Dis 74(9):1691–1696

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210008, Jiangsu, China

    Sajan Shrestha & Jinping Zhang

  2. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 639 Longmian Avenue, Jiangning, Nanjing, 211198, China

    Sajan Shrestha, Jing Zhao & Changqing Yang

Authors
  1. Sajan Shrestha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Changqing Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jinping Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Sajan Shrestha designed research and prepared the manuscript; Sajan Shrestha and Jing Zhao collected, analyzed, and interpreted the data; and Jinping Zhang and Changqing Yang monitored, supervised, and critically revised the whole work. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Changqing Yang or Jinping Zhang.

Ethics declarations

Ethical standards

The manuscript does not contain clinical studies or patient data.

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Shrestha, S., Zhao, J., Yang, C. et al. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 39, 2139–2150 (2020). https://doi.org/10.1007/s10067-020-04986-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-04986-9

Keywords

Search

Navigation